How a clinician actually chooses peptides

The Core Idea

A protocol is a system, not a menu

The peptide internet treats compound selection like ordering off a menu — pick what sounds good, stack a few, hope they get along. A clinician does the reverse. The compound is the last thing decided, not the first. What comes before it is a chain of reasoning: what is this person actually trying to fix, what one compound leads that fix, what in their history changes or forbids it, how much can the plan hold, and what rules can never be broken. This page walks that chain, step by step.

Ten categories, not a hundred compounds

A person doesn't arrive with a compound in mind — they arrive with a goal: lose fat, sleep better, heal an injury, think clearly, age well. The first move is translating those goals into biological categories, because that's how a clinician reasons — by the system a compound acts on, not its name.

Each symptom, at each severity level, contributes a weighted score to one or more categories. The same intake always produces the same matched categories — selection is never a mood or a guess.

One compound leads. The rest earn their place.

Once a category is matched, it gets an anchor — the compound that always leads that category. Everything else is conditional: it only joins the protocol when a specific trigger in the person's intake or labs justifies it. This is the discipline that separates a protocol from a pile.

Twenty-one conditions that change or stop the plan

Before anything is finalized, the plan runs a safety screen. Certain histories don't just add a warning — they suppress a compound entirely or flag it for physician oversight. This is the step that makes selection safe, and it's the step no self-directed stack ever runs.

The full screen covers twenty-one conditions — diabetes and glucose medications, kidney and liver disease, IBD, gastroparesis, osteoporosis, injectable-reaction history, medication allergies, and more — each mapped to specific suppress-or-flag rules.

What the plan can actually hold

A protocol isn't "everything that could help" — it's what fits inside real constraints. Two limits govern this:

Compound count caps

A 30-day plan holds a practical maximum of five to seven compounds. A 90-day plan can carry eight to ten — but across phased stages, not all at once. When three or more categories match, the highest-severity goals win the limited slots.

Phased sequencing (90-day arcs)

Serious protocols don't front-load everything. They sequence: calm the inflammation, protect the gut, anchor the primary driver, then layer recovery and optimization. The order in which compounds enter is itself a clinical decision — establish, build, complete.

The rules that never bend

Some rules override everything else — no goal, budget, or preference unlocks them. These are the locks that keep every protocol safe and consistent:

• GLP-1 selection is fixed: goal delta ≥25 lb → tirzepatide; <25 lb → retatrutide; diabetes → semaglutide. Never two GLP-1s together.
• GLP-1s are once weekly only — never a 5-on/2-off pattern.
• GHK-Cu is a solo syringe, always — the copper content means it never shares.
• GH peptides (CJC-1295, ipamorelin, tesamorelin) are dosed fasted at bedtime — no food 90 minutes either side.
• Certain compounds are suppressed forever — safety and evidence rules that don't reopen.
• Epithalon runs 10 consecutive days, then repeats quarterly — never continuous.

Syringe compatibility — a rule most people never learn

The Payoff

Same inputs, same protocol — every single time

Here's what all five steps add up to, and why it matters: this is deterministic. Ask a chatbot the same peptide question twice and you'll get two different answers. Run the same intake through this logic twice and you get the identical protocol — because it's rules, not improvisation. That reproducibility is the difference between a guess dressed up in confidence and a decision you can hand to your own physician and defend line by line.

Not Sure Where You Fit?

About the Author

Full Disclaimer